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ABSTRACT 
Study Objectives: Sleep problems are often undetected in adults with Down syndrome (DS). 
Our objective was to determine the prevalence of sleep disorders in adults with DS through 
self-reported and objective sleep measures. 
Methods: We performed a community-based cross-sectional study of 54 adults with DS not 
referred for sleep disorders. Two polysomnography (PSG) sleep studies were performed. Sleep 
quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was 
evaluated using the Epworth Sleepiness Scale (ESS) and the risk for the sleep apnea syndrome 
(OSA) was identified using the Berlin Questionnaire (BQ). Participants’ sleep/wake pattern was 
assessed from sleep diaries and by wrist actigraphy. PSQI, ESS, and PSG measures were 
compared with 35 sex-, age-, and body mass index-matched patients in the control groups. 
Results: In PSG measures, adults with DS showed lower sleep efficiency (69 ± 17.7 versus 81.6 
± 11; P < .001), less rapid eye movement sleep (9.4 ± 5.8 versus 19.4 ± 5.1; P < .001), a higher 
prevalence of OSA (78% versus 14%; P < .001), and a higher apnea-hypopnea index (23.5 ± 24.5 
versus 3.8 ± 10.5; P < .001) than patients in the control group. In the DS group, the 
questionnaires (mean PSQI 3.7 ± 2.9; mean ESS 6.3 ± 4.5 and mean BQ 1 ± 0) did not reflect the 
sleep disturbances detected on the PSG. Actigraphy data recorded daytime sleep that was not 
self-reported (118.2 ± 104.2 minutes). 
Conclusions: Adults with DS show severe sleep disruption and a high prevalence of OSA, 
undetected by self-reported sleep measures. Actigraphy, PSG, and validated simplified devices 
for screening OSA should be routinely recommended for this population because treatment of 
sleep disorders can contribute to healthy aging. 
Keywords: actigraphy, aging, Down syndrome, obstructive sleep apnea, polysomnography, 
self-reported sleep quality, sleep disruption 
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BRIEF SUMMARY 
Current Knowledge/Study Rationale: The few studies to date on sleep disorders in adults with 
Down syndrome (DS) are mainly descriptive, based on self-reported measures only, and 
performed in small samples. Objective polysomnography and actigraphy studies in this setting 
are therefore lacking. This study determined the prevalence of sleep disorders in adults with 
DS using both self-reported and objective sleep measures. 
Study Impact: This is an objective, community-based sleep study conducted in a large sample 
of adults with DS. Although the participants were not referred for sleep disorders, we 
observed a high prevalence of sleep disruption, obstructive sleep apnea, and napping during 
the day. These findings were not detected by current self-reported sleep measures or reported 
by caregivers. 
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INTRODUCTION 
Life expectancy for patients with Down syndrome (DS) has increased dramatically in 
recent years and is now over 60 years in developed countries.1 This advance is largely because 
of improvements in medical care provided for associated comorbidities. Treatment of sleep 
disorders in patients with DS may further help improve cognition, general health, and quality 
of life for this population.2,3 However, consensus based sleep guidelines for adults with DS are 
lacking. Sleep problems are commonly reported in the DS population, but unlike for children 
with DS,4–7 data on the prevalence, severity, and health consequences of sleep disorders in 
adults with DS are scarce.8 Most previous studies have been descriptive and based on small 
samples using self-reported sleep measures in cohorts with mixed intellectual disabilities.3,9 
These reports, based on caregiver ratings, display a wide range in the prevalence of sleep 
disorders: the prevalence of sleep apnea ranges from 13.3% to 40% and behavioral sleep 
disturbances range from 22.7% to 60%.3,10,11 However, in the adult population, these figures, 
which are based on clinical reports and self-reported sleep measures, may be underestimated 
when compared to objective sleep data, as is the case in the pediatric DS population.6  
To our knowledge, only two previous studies have objectively evaluated sleep in adults 
with DS using full polysomnography (PSG), the standard reference technique for diagnosing 
sleep disorders. Both studies evidenced a high prevalence of obstructive sleep apnea 
(OSA).12,13 In these studies, however, sample size was small, adults with DS were relatively 
young (12 and 6 participants with a median age of 33 and 35 years, respectively),12,13 sex 
differences were not taken into account, and participants were assessed only for OSA. 
Recently, the Adult Health Care Workgroup of the Down Syndrome Medical Interest Group 
USA (DSMIG-USA) identified sleep apnea as a co-occurring medical condition and paid special 
attention to adults with DS, though the resulting data are somewhat sparse because of the 
small size and selection bias of the studied samples. 15 The group highlighted the need to 
confirm these objective sleep findings in a larger, community-based population of adults with 
DS in order to generalize sleep data and develop specific screening and treatment guidelines 
for OSA.  
The objective of the current study was to characterize and determine the prevalence of 
sleep disorders in a large, community-based sample of adult participants with DS and to 
compare the results obtained with self-reported and objective sleep measures. 
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METHODS  
Study design and participants 
Participants with DS were included from the Down Alzheimer Barcelona Neuroimaging 
Initiative (DABNI), a research program developed by the Barcelona Down Medical Center 
(BDMC) of the Catalan Down Syndrome Foundation together with Hospital de la Santa Creu i 
Sant Pau in Barcelona (HSCSP).15,16  
The BDMC is a non-profit organization that provides medical and social support to people 
with DS in Catalonia.  Its active database includes more than 2,000 individuals. The BDMC and 
HSCP have jointly developed two projects: the Health Plan for Adults with DS to screen for 
medical comorbidities and DABNI17 and a research initiative for the study of Alzheimer 
disease in patients with DS. The former of these two projects, the Health Plan for Adults with 
DS, is population based and it includes more than 500 individuals. From September 2014 to 
June 2016, when the data for the current manuscript were collected, 380 participants 
participated in the DABNI research project, 54 of whom agreed to participate in the additional 
sleep study.  
All participants underwent a full medical, neurological, and neuropsychological 
evaluation. A sleep specialist explained the study in detail to all participants with DS and their 
legal tutors prior to their inclusion in the study. Written informed consent was obtained from 
all parents or legal caregivers and assent was acquired from the participant. The study was 
approved by the local ethics committee following the principles stated in the Declaration of 
Helsinki. 
Inclusion criteria were good general condition, age older than 18 years, and ability to 
understand and accept the study procedures. We included only participants with mild to 
moderate mental retardation according to International Classification of Diseases, Tenth 
Edition criteria (Intelligence Quotient scores > 34). Exclusion criteria were severe mental 
retardation, history of conditions that could affect brain structure or function (such as stroke 
or traumatic brain injury), and the use of new psychoactive drugs in the 3 months preceding 
the sleep studies. Sleep complaints were not considered in the inclusion criteria. 
A control group matched for age, sex and body mass index (BMI) was selected 
retrospectively from a pool of volunteers from the general population who had performed 
nocturnal PSG in the sleep laboratory at the Drug Research Center of the Research Institute at 
Hospital de la Santa Creu i Sant Pau. The medical history of these participants was recorded 
and all had physical and neurological examinations before the PSG. We excluded participants 
with a history of chronic medical disorders such as chronic obstructive pulmonary disease, 
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uncontrolled diabetes, cardiovascular disease, or psychiatric disorders. Participants under 
treatment for sleep disorders and those with any neurodegenerative diseases or with 
neurological conditions that could affect brain function, such as stroke, were also excluded. 
Sleep Evaluation 
All participants with DS underwent a full sleep evaluation. This included a sleep interview 
with a sleep specialist, and a self-reported and objective evaluation of nocturnal sleep and the 
circadian sleep-wake cycle. Nocturnal sleep was studied objectively by means of two full video 
PSG studies performed 1 week apart. Sleep/wake cycles were collected via sleep diaries and 
actigraphy was conducted in between the two PSG studies. Figure 1 shows an outline of the 
procedure. 
 
 
Subjective sleep questionnaires 
All participants were given a notebook that included sleep questionnaires and sleep 
diaries to be completed by the caregivers. The sleep questionnaires included the validated 
Spanish version of the following scales: the Pittsburgh Sleep Quality Index (PSQI) to assess 
patients’ self-reports of sleep quality;18 the Epworth Sleepiness Scale (ESS) to evaluate 
somnolence (with a modification of the last question about the DS person as a passenger in a 
car while stopped for a few minutes in traffic);29 and the Berlin Questionnaire (BQ) to identify 
participants at risk for the sleep apnea syndrome.20,21 
Actigraphy and sleep diaries 
During the week between the two PSG studies, participants wore a wrist actigraph 
(Actigraph, Actilife 5). They also completed a sleep diary with daily reports about quality of 
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sleep and sleep initiation, and maintenance variables: bedtime, wake time, sleep latency (SL), 
and wake after sleep onset (WASO). 
Nocturnal polysomnography (PSG) 
Sleep recordings were performed in individual, sound-attenuated, temperature-regulated 
rooms in the sleep laboratory at our sleep unit. Participants were continuously supervised by 
qualified technical staff and were recorded on video/audio with the use of an infrared camera. 
PSG tests were started at their median bedtime as defined by the prospective diary collection, 
with a recording time of 8 hours. To minimize PSG-related disturbances, the first PSG session 
was an adaptation night to familiarize participants with the laboratory and recording 
procedures. The second PSG was the target night from which results were obtained for the 
final sleep evaluations. The morning after each of the two PSG nights, all participants 
completed a questionnaire about their sleep quality in the laboratory. We compared this 
questionnaire with their usual reported sleep quality at home.  
PSG sleep data were acquired by means of the Compumedics E Series System 
(Compumedics, Victoria, Australia). All-night video PSG-recordings included: (1) 19 
electroencephalography channels referenced to averaged mastoid electrodes (A1-A2) 
according to the international 10–20 system; (2) 2 electrooculographic channels; (3) 4 surface 
electromyographic channels: 2 from the mentalis, 1 from the right anterior tibialis and 1 from 
the left anterior tibialis in lower limbs; and (4) 6 channels to monitor respiratory function: 1 for 
oximetry, 2 for oronasal airflow using a thermistor and nasal cannula, 2 to record 
thoracoabdominal movements by inductance plethysmography, and a microphone at the 
suprasternal notch to detect snoring.  
Sleep stages were visually scored for 30-second epochs according to the guidelines of the 
American Academy of Sleep Medicine (AASM).22 Profusion Sleep Software was used 
(Compumedics PSG3 version 3.4). Scoring was performed by an experienced sleep technologist 
and later reviewed by an accredited sleep somnologist.  
Arousals were defined using AASM criteria. Respiratory variables included the apnea-
hypopnea index (AHI), defined as the sum of all apneas (> 90% reduction in airflow for > 10 
seconds) and all hypopneas (airflow reduction greater than 30% for at least 10 seconds with an 
oxygen saturation decrease of approximately 3% or a cortical awakening) per hour of sleep, 
and mean oxygen saturation during the night (SpO2).23  
Periodic limb movements and abnormal rapid eye movement (REM) sleep behavior 
disorder were defined according to the International Classification of Sleep Disorders.24  
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Sleep data from the control group were obtained retrospectively. The control group 
underwent a 1-night PSG study performed using the same monitoring techniques as the DS 
group and ESS and PSQI scores were obtained. This group did not provide actigraphy data or 
answer the BQ. 
Statistical Analyses 
Statistical analyses were performed using SPSS version 23 software (IBM Corp., Armonk, 
New York, United States). Demographics and sleep scores were compared between groups by 
means of t tests for repeated measures. The statistical threshold was set at .05. To assess the 
differences between the various sleep techniques performed in participants with DS, general 
lineal models with one within-participant factor (techniques, three levels) were applied 
separately to each sleep variable. For all variables, results were pair-compared by means of the 
t test for repeated measures if required. Greenhouse-Geisser correction was used. The 
Pearson correlation was applied to evaluate the relationship between sleep variables. 
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RESULTS 
Participant characteristics 
Table 1 shows the participants’ demographic characteristics.  
 
 
The mean age of participants with DS was 39.6 (range 20–62 years). Ten participants were 
obese (BMI > 30 kg/m2), 19 were overweight, and 18 had a normal BMI (BMI 18 to < 25 
kg/m2).  
The oropharyngeal examination showed 6 participants (12.7%) had a Mallampati class III 
airway and 41 participants (87.2%) had a Mallampati class IV airway. Four had undergone 
adenoidectomy, and one had undergone tongue reduction. Clinically, 17 participants 
presented a nonclinically significant heart murmur and 2 participants had undergone surgery 
for a congenital heart defect with minimal residual cardiac insufficiency. Five patients were 
being treated with levothyroxine, 12 with antidepressants, 2 with benzodiazepines, 5 with 
antipsychotics, 1 with gabapentin, and 1 with topiramate. Twelve participants were 
medication free. There were no significant differences in the sociodemographic variables in 
sleep measures (except for the periodic limb movement index in PSG data; see next 
paragraphs) among participants with DS on antidepressant medication and those who were 
not taking antidepressants (Table S1 in the supplemental material). Six adults with DS had 
Alzheimer disease dementia, but their exclusion did not change the results (Table S2 in the 
supplemental material).  
Forty participants (85.1%) lived at home with a family member, 4 (8.5%) lived in an 
independent but supervised apartment, and 3 (6.4%) lived in a nursing home. Thirty-five 
individuals in the control group were recruited from the sleep laboratory database. No 
statistically significant differences were observed between the DS group and control group 
regarding mean age: 39.2 years (range 18–71) (P = .89). Neither were statistically significant 
differences found regarding mean BMI: 25.4 (20–35.1) kg/m2,   (P = .14).  
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Subjective sleep data 
Sleep questionnaires were appropriately completed by caregivers for 40 participants with 
DS. Compared to patients in the control group, participants with DS had significantly lower ESS 
(P = .04) and PSQI (P = .002) scores. Table 2 shows the mean global sleep questionnaire scores 
for both groups. In the DS group, the mean values of all self-reported sleep measures were 
within normal limits: (1) ESS suggested somnolence (ESS > 10) in 8 participants (17.0%) but no 
participants presented severe somnolence (ESS > 16); (2) PSQI suggested sleep disorders (PSQI 
> 5) in 9 participants (19.2%); and (3) BQ suggested sleep apneas in 2 participants (4.3 %). 
 In the control group, the mean ESS score was within the normal range (ESS < 10). The 
mean PSQI score was slightly above the pathological score (PSQI > 5) but it was within the 
range described in previous large scale PSQI normative studies in the general population.25  
No statistical differences between males and females were observed for any of these 
variables in either group. 
Sleep diary data 
Table 3 shows sleep initiation and maintenance parameters from sleep diaries from 
participants with DS. The sleep diaries showed normal SL (< 20 minutes) and normal sleep 
efficiency (SE; > 90%). Two participants had an SL longer than 30 minutes, and 10 participants 
had an SE under 85%. 
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Actigraphy data 
The wrist actigraphy results from the participants with DS, presented in Table 3, show a 
mean SL slightly above the normal range (> 20 minutes), with reduced SE (< 85%). Mean 
daytime napping was 118.2 ± 104.2 minutes. Estimated total sleep time (TST) over 24 hours 
(mean nocturnal TST + mean daytime napping) obtained by actigraphy data was 501minutes 
(383.9 and 118 minutes, respectively). 
Polysomnography data  
Seven of the initial 54 participants with DS did not complete the second PSG night. Full 
PSG data from both nights were obtained for the remaining 47 adults. PSG was well tolerated, 
though participants had difficulty sleeping the first night. We observed differences in 
maintenance of sleep variables between the two nighttime PSG tests. Sleep efficiency on the 
second night increased 4.2% on average compared with the first night, but this difference did 
not reach statistical significance (P = .15). On the second night, 25 participants with DS (53.2%) 
presented prolonged SL (> 20 minutes) and 18 (38.3%) had an early awakening with a mean 
early wake time of 9.2 minutes (range 0–115). Sleep efficiency was under 85% in 74.5% of the 
participants. Sleep quality on both PSG nights was scored by the participants as similar to that 
at home.  
Sleep initiation and maintenance variables  
Results from the three sleep monitoring techniques performed in participants with DS 
regarding sleep initiation and maintenance differed significantly, as shown in Table 3. Time in 
bed, TST, and SE were significantly higher in the sleep diary than in the actigraphy and 
nighttime PSG data. SE was lower in only 35.3% of participants according to their sleep diaries, 
compared to 87.8% according to actigraphy and 74.5% according to PSG data. Similarly, SL and 
WASO were significantly lower in sleep diaries than in actigraphy and PSG data. 
Sleep architecture variables 
Compared to patients in the control group, participants with DS showed a decrease in TST 
and in SE, and an increase in SL, REM, SL, and WASO, as shown in Table 4.  
Participants with DS also showed significantly higher percentages of stage N1 and N3 
sleep, and more decreases in REM sleep than those in the control group. Specifically, in 
participants with DS, the percentage of REM sleep was under 20% in all but 1 participant, and 
3 participants did not experience REM sleep. We found no significant differences in the mean 
REM percentage between those who were taking antidepressants and those who were not      
(P = .358). We did not find any correlation between the percentage of REM sleep and age         
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(P = .68). The arousal index score was higher in the DS group than in the control group, mainly 
because of a higher AHI in the DS group.  
Men with DS had a significantly higher percentage of stage N1 sleep than women with DS 
(P = .001). In the control group, women had a significantly longer SL (31.5 ± 21) than men (16.7 
± 11.16) (P = .018). 
 
Sleep respiratory variables 
Compared with the control group, participants with DS presented more sleep respiratory 
alterations, with a higher AHI and greater decreases in oxygen saturation during sleep (Table 4). 
These differences remained significant after age, sex, and BMI were included as covariates in 
the model. The median AHI adjusted for the covariables age, sex, and BMI was 22.81 in the DS 
group and 5.46 in the control group.  
Thirty-four participants with DS (78.7%) and five patients in the control group (14%) had 
OSA. OSA was severe in 15 participants with DS (AHI > 30 events/h), moderate in 8                    
(AHI < 15–29.99 events/h), and mild in 11 (AHI 5–14.99 events/h). We did not find central 
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sleep apnea syndrome (> 5 events/h) or periodic breathing disorder in any participants. In the 
control group, OSA was moderate in one participant and mild in four participants.  
In both groups, the AHI correlated positively with WASO, stage N2 sleep, number of shift 
changes, oxygen desaturation index, and total arousal, and inversely with stage N3 sleep and 
basal and minimal oxygen saturation during sleep (P < .001). In the group with DS we found a 
significant correlation between AHI and BMI (r = .5, P < .001), but only a tendency toward a 
correlation between AHI and age (r = .26, P = .07), sex, and percentage of REM sleep (r = −.04, 
P = .75). We did not find any correlation between AHI and the self-reported sleep 
questionnaires, though we did observe a negative correlation between stage N3 sleep and ESS 
scores (r = −.348, P = .017).  
In the control group, the AHI score correlated with age (P < .001, r = .58), but not with BMI 
(P = .12, r = .27). 
Abnormal behaviors during sleep and sleep-related movement disorders 
Two participants reported nightmares but these were not reflected in the PSG recordings. 
Twenty experienced sleep talking; this occurred mainly during superficial non-rapid eye 
movement stages and was generally incomprehensible. In 3 of the 47 participants, some 
isolated movements during REM sleep were observed. However, no episodes fulfilled the 
diagnostic criteria for sleepwalking, REM sleep behavior disorder, or epileptic seizures. 
Repetitive swallowing and chewing movements, without bruxism features, were observed in 
five participants during wake time and also during sleep time on the PSG. No self-reported 
clinical symptoms suggestive of restless leg syndrome were reported by the participants. 
Periodic limb movements (> 5 events/h) were present in 10 participants and only 1 participant 
had more than 15 events/h. Individuals with DS not taking antidepressant medication had 
higher periodic limb movements and higher periodic limb movement arousal index scores than 
those taking antidepressant medication (Table S1). 
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DISCUSSION 
The results of this study suggest that adults with DS have severe sleep disorders that are 
not detected by current self-reported sleep measures or reported by caregivers. Although the 
participants with DS were not referred because of suspicion of a sleep disorder, 74.5% had 
poor SE and 78% had OSA. The actigraphy data also recorded lower SE and higher napping 
than that reported in the sleep diaries by the caregivers.  
A major finding in this study is that the self-reported sleep questionnaires did not reflect 
the sleep disturbances in this population. One reason could be that the questionnaires reflect 
the caregivers’ perceptions and are therefore subjective. As validated questionnaire-based 
tools to screen for sleep disturbances in adults with DS are lacking, we used the same 
questionnaires as in the control group.  
The PSQI sleep questionnaire excluded the presence of sleep disorders and indicated 
good sleep quality. Self-reported sleep quality has been related to the amount of slow wave 
sleep (SWS, or stage N3 sleep).26 We did not, however, find any correlation between SWS and 
PSQI scores, but PSQI scores did correlate with the sleep diaries (P = .004, r = −.447), a s has 
been shown in the general population.27 More surprisingly, the Berlin questionnaire, which has 
proved highly sensitive in detecting OSA in the general population,28 classified the possibility of 
participants with DS having sleep apneas as low. This suggests caregivers may underreport 
snoring and fatigue, the typical signs of OSA, in this population. The adapted ESS also failed to 
detect somnolence in the DS group, as in previous studies.10,29 We speculate that the DS 
caregiver does not generally recognize sleepiness and frequently attributes quiescent states to 
aging or normal apathy.  
Participants did not report problems in their sleep diaries regarding falling to sleep or 
staying asleep. Although they spent a median of 9 hours in bed, 1 hour more than their age-
matched general population,30 this longer time in bed did not increase awakenings during the 
night or reduce self-reported SE. However, participants and their caregivers overestimated TST 
and sleep quality, most likely because sleep disturbances are perceived in cases of nocturnal 
agitation but not during peaceful insomnia, as in the general population. Conversely, when 
evaluated with objective measures, almost all participants presented with problems initiating 
and maintaining sleep.  
The decrease in nocturnal TST detected from PSG data could be partially explained by the 
daytime napping suggested by actigraphy data and the consequent reduction in sleep 
homeostatic pressure.31 Indeed, PSG data alone could underestimate the TST. We observed a 
discrepancy between the absence of self-reported daytime naps and the long daytime sleep 
that was detected by actigraphy data (results not shown). Nevertheless, other objective 
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measures of sleepiness, such as the Multiple Sleep Latency Test, should be performed to 
differentiate real sleep from periods of quiet restfulness to obtain a more accurate estimate of 
the total amount of sleep time over 24 hours, and to compare this with that in the general 
population.30 Nocturnal TST was nevertheless reduced even in individuals who did not nap. In 
addition to the structural brain anomalies associated with DS, disturbances in the cholinergic 
and serotonergic systems and deterioration of the cholinergic basal forebrain neuronal 
function may also affect the sleep/wake pattern.32 Specifically, a decrease in TST in people 
with DS could also be related to variants of the human clock gene in circadian rhythm sleep. 
Recently published data from DS mouse models expressing sleep-related phenotypes 
comparable with rest/activity patterns in participants with DS might be helpful in future 
research.33  
Aging in the general population is associated with a physiological decrease in SWS and 
REM sleep as sleep becomes more fragmented,30 with a notable reduction in REM sleep in 
Alzheimer disease.34 Senescence in individuals with DS occurs earlier than in the general 
population.35 The PSG results in our study suggest a premature sleep aging process in DS, with 
chronological age not matching physiological age, and changes in sleep patterns appearing 
earlier than in the general population. Moreover, presenile-onset Alzheimer disease will 
develop in most people with DS. Dementia is associated with more sleep disturbances than 
expected with normal aging in the general population.36 Similar data, however, are not yet 
available for participants with DS. Further studies are necessary to assess the impact of 
Alzheimer disease on sleep in the DS population.  
In line with previous objective data12,13 we found that OSA was the main sleep disturbance 
in the DS population (78%). This figure is considerably higher than the 14% in the control group, 
which was also in line with the prevalence in the general population.37  
We observed only a tendency for correlation between OSA and age in our DS group. It did 
not reach the significance reported in children with DS4,6 or in the general population,37 but 
this may be caused by the lower power of our sample. We did observe a relationship between 
OSA and BMI, as commonly reported in the general population38 and in participants with 
DS.12,13 Aging in DS is associated with hypothyroidism and obesity, both of which are known 
risk factors for OSA.39 Both of these conditions worsen the upper airway narrowing that is 
present from infancy in participants with DS due to their craniofacial and functional 
abnormalities.6,7 Further studies may determine whether dietary control or weight loss 
through exercise in adults with DS prevents or decreases OSA severity, as measured by 
reductions in the AHI and observed in the general population.39  
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Another point of note is that the participants in our study had not been referred because 
of suspicion of OSA. Our findings show that the prevalence of sleep apnea in adults with DS is 
high whether or not they are referred for suspected OSA. These data stress the need for a 
change in clinical practice and for routine PSG screening for sleep apnea in adults with DS.  
We recorded few abnormal motor behaviors during sleep. The most frequent event was 
sleeptalking. Despite the relative increase in slow wave sleep, we found no episodes of non-
rapid eye movement-related parasomnia or REM sleep behavior disorder in the short periods 
of REM sleep recorded. Periodic limb movements during sleep were infrequent in our findings. 
 Our results have several clinical implications. First, they indicate that sleep problems are 
underrecognized by patients and caregivers. This could be because they are masked by the 
patients’ global intellectual disability, because they are chronically present, or because they 
are accepted by caregivers as part of the aging process. Second, most of our participants with 
DS had severe OSA, a disorder associated with a higher risk of mortality.40 Although the 
average life expectancy has increased dramatically for people with DS in recent years, it is still 
20 years less than that for the general population.35 Monitoring treatable OSA risk factors and 
early detection and correction of OSA could help minimize derived comorbidities and improve 
life expectancy. Sleep disturbances in adults with DS may have a greater effect on physical, 
mental, and emotional health than in the general population,2,8,41 leading to a higher incidence 
of daytime behavioral problems, an increased risk of accidents, and more visits to physicians.3 
Third, our results highlight the need to design questionnaires to specifically screen for sleep 
disturbances in adults with DS. Nevertheless, until such scales or other more practical 
screening approaches are available,42 we suggest PSG be routinely recommended in this 
population. Fourth, these sleep-based data may be useful for developing guidelines and 
programs for the prevention, screening, and treatment of sleep disorders in the adult DS 
population. Treating sleep disorders may improve cognition and quality of life in adults with 
DS,43 helping them to achieve their full potential in terms of mental and physical health as they 
age.  
This study has three main limitations: the absence of actigraphy and sleep diaries in the 
control sample, the limited sample size, and the inclusion of both premenopausal and 
postmenopausal women. The availability of actigraphy and sleep diaries would have allowed 
evaluation of the differences in the sleep-wake pattern between the DS group and the general 
population. Validation of actigraphy data through comparison with PSG data in the adult DS 
population is still needed. Larger studies are also required to compare the results of PSG, 
actigraphy, and sleep diaries in the DS population in order to validate their usefulness in 
detecting sleep disorders, as has been demonstrated for the general population.44 Regarding 
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the limited sample size, this may have limited the power to establish significant differences in 
some variables. Finally, postmenopausal women in the general population have a higher risk of 
the development of OSA,45 but although we did not perform any specific determinations of sex 
hormones, we found no notable sex difference for any of the sleep variables analyzed.  
Our study also has several strengths. It compares self-reported and objective sleep 
measures in a large sample of adults with DS, and there was no bias toward sleep disorders. 
Furthermore, we performed a complete PSG adaptation night, which allowed us to achieve 
higher SE on the second PSG night. Finally, the actigraphy recordings collected over 7 days 
provided further information about habitual sleep-wake patterns.  
In conclusion, we found a high prevalence of sleep disorders in adults with DS. Seventy-
four percent of the adults showed poor SE and 78% had OSA that was not detected by current 
self-reported sleep measures. OSA was severe in 30% of the participants. These findings 
support the notion that the adult DS population should undergo routine objective screening 
methods for sleep disturbances as adequate treatment might promote healthy aging. 
ABBREVIATONS 
AHI, apnea-hypopnea index 
BQ, Berlin Questionnaire 
DS, Down syndrome 
ESS, Epworth Sleepiness Scale 
OSA, obstructive sleep apnea 
PSG, polysomnography 
PSQI, Pittsburgh Sleep Quality Index 
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